Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China; Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing, 100700, China; Beijing University of Chinese Medicine, Beijing, 100029, China.
Beijing University of Chinese Medicine, Beijing, 100029, China; China-Japan Friendship Hospital, Beijing, 100029, China.
Phytomedicine. 2023 Jan;108:154530. doi: 10.1016/j.phymed.2022.154530. Epub 2022 Nov 3.
Intracerebral hemorrhage (ICH) is a life-threatening stroke subtype with high rates of disability and mortality. Naoxueshu oral liquid is a proprietary Chinese medicine that absorbs hematoma and exhibits neuroprotective effects in patients with ICH. However, the underlying mechanisms remain obscure.
Exploring and elucidating the pharmacological mechanism of Naoxueshu oral liquid in the treatment of ICH.
The Gene Expression Omnibus (GEO) database was used to download the gene expression data on ICH. ICH-related hub modules were obtained by weighted gene co-expression network analysis (WGCNA) of differentially co-expressed genes (DEGs). The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted using the obtained key modules to identify the ICH-related signaling pathways. Network pharmacology technology was applied to forecast the targets of Naoxueshu oral liquid and to establish a protein-protein interaction (PPI) network of overlapping targets between Naoxueshu oral liquid and ICH. Functional annotation and enrichment pathway analyses of the intersectional targets were performed using the omicsbean database. Finally, we verified the therapeutic role and mechanism of Naoxueshu oral liquid in ICH through molecular docking and experiments.
Through the WGCNA analysis, combined with network pharmacology, it was found that immune inflammation was closely related to the early pathological mechanism of ICH. Naoxueshu oral liquid suppressed the inflammatory response; hence, it could be a potential drug for ICH treatment. Molecular docking further confirmed that the effective components of Naoxueshu oral liquid docked well with CD163. Finally, the experimental results showed that Naoxueshu oral liquid treatment in the ICH rat model attenuated neurological deficits and neuronal injury, decreased hematoma volume, and promoted hematoma absorption. In addition, Naoxueshu oral liquid treatment also significantly increased the levels of Arg-1, CD163, Nrf2, and HO-1 around hematoma after ICH.
This study demonstrated that Naoxueshu oral liquid attenuated neurological deficits and accelerated hematoma absorption, possibly by suppressing inflammatory responses, which might be related to the regulation of Nrf2/CD163/HO-1 that interfered with the activation of M2 microglia, thus accelerating the clearance and decomposition of hemoglobin in the hematoma.
脑出血(ICH)是一种危及生命的中风亚型,其残疾和死亡率均很高。脑血疏口服液是一种中药专利药物,可吸收血肿,并对 ICH 患者具有神经保护作用。然而,其潜在机制尚不清楚。
探索和阐明脑血疏口服液治疗 ICH 的药理机制。
使用基因表达综合数据库(GEO)下载 ICH 的基因表达数据。通过差异共表达基因(DEGs)的加权基因共表达网络分析(WGCNA)获得 ICH 相关的枢纽模块。使用获得的关键模块对基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析进行分析,以确定 ICH 相关的信号通路。应用网络药理学技术预测脑血疏口服液的靶标,并建立脑血疏口服液与 ICH 重叠靶标的蛋白质-蛋白质相互作用(PPI)网络。使用 omicsbean 数据库对交集靶标进行功能注释和富集通路分析。最后,通过分子对接和实验验证脑血疏口服液在 ICH 中的治疗作用和机制。
通过 WGCNA 分析,结合网络药理学,发现免疫炎症与 ICH 的早期病理机制密切相关。脑血疏口服液抑制炎症反应,因此可能是治疗 ICH 的潜在药物。分子对接进一步证实,脑血疏口服液的有效成分与 CD163 结合良好。最后,实验结果表明,脑血疏口服液治疗 ICH 大鼠模型可减轻神经功能缺损和神经元损伤,减少血肿体积,并促进血肿吸收。此外,脑血疏口服液治疗还显著增加了 ICH 后血肿周围 Arg-1、CD163、Nrf2 和 HO-1 的水平。
本研究表明,脑血疏口服液减轻了神经功能缺损,加速了血肿吸收,可能是通过抑制炎症反应来实现的,这可能与 Nrf2/CD163/HO-1 的调节有关,干扰 M2 小胶质细胞的激活,从而加速血肿中血红蛋白的清除和分解。